journal of men's health
Volume 7, Issue 1 , Pages 85-91 , March 2010

High-sensitivity C-reactive protein and endothelin-1 in age-related macular degeneration

  • Amir Ghorbanihaghjo, PhD

      Affiliations

    • Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran
    • ,
  • Alireza Javadzadeh, MD

      Affiliations

    • Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran
    • Corresponding Author InformationCorresponding author.
    • ,
  • Nadereh Rashtchizadeh, PhD

      Affiliations

    • Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran
    • ,
  • Hassan Argani, MD

      Affiliations

    • Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran
    • ,
  • Sima Masoodnia, MD

      Affiliations

    • Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran
    • ,
  • Nariman Nezami, MD

      Affiliations

    • Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran

Received 8 July 2009 ,Revised 30 September 2009 ,Accepted 9 October 2009.

References 

  1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486–495
  2. Kuehn BM. Gene discovery provides clues to cause of age-related macular degeneration. JAMA. 2005;293:1841–1845
  3. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353–363
  4. Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets. 2007;11:625–639
  5. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205–210
  6. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553–561
  7. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology. 2005;112:2076–2080
  8. Mori F, Konno S, Hikichi T, Yamaguchi Y, Ishiko S, Yoshida A. Pulsatile ocular blood flow study: decreases in exudative age related macular degeneration. Br J Ophthalmol. 2001;85:531–533
  9. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol. 2005;40:277–287
  10. Bressler NM, Bressler SB. Preventative ophthalmology. Age-related macular degeneration. Ophthalmology. 1995;102:1206–1211
  11. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–374
  12. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385–414
  13. Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology. 2007;114:1722–1727
  14. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL Age-Related Eye Disease Study Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. Ophthalmology. 2005;112:533–539
  15. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents?. Ophthalmic Epidemiol. 1999;6:125–143
  16. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology. 2007;114:1143–1150
  17. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704–710
  18. Cosin-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol. 2003;41:1468–1474
  19. Lee HB, Pulido JS, McCannel CA, Buettner H. Role of inflammation in retinal vein occlusion. Can J Ophthalmol. 2007;42:131–133
  20. Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther. 2006;8:28–36
  21. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–2138
  22. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol. 2007;16:14–21
  23. Vainas T, Stassen FR, de Graaf R, Twiss EL, Herngreen SB, Welten RJ, et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005;42:243–251
  24. Ersoy Y, Bayraktar NM, Mizrak B, Ozerol IH, Gunal S, Aladag M, et al. The level of endothelin-1 and nitric oxide in patients with chronic viral hepatitis B and C and correlation with histopathological grading and staging. Hepatol Res. 2006;34:111–116
  25. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci. 2004;25:219–224
  26. Shah R. Endothelins in health and disease. Eur J Intern Med. 2007;18:272–282
  27. Katayama T, Yano K, Nakashima H, Takagi C, Honda Y, Suzuki S, et al. Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. Circ J. 2005;69:654–658
  28. Wunder DM, Yared M, Bersinger NA, Widmer D, Kretschmer R, Birkhäuser MH. Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. Eur J Endocrinol. 2006;155:137–142
  29. Folsom AR, Golden SH, Boland LL, Szklo M. Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women. Eur J Epidemiol. 2005;20:1015–1022
  30. Wang X, Simpkins JW, Dykens JA, Cammarata PR. Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci. 2003;44:2067–2075
  31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  32. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 1998;116:583–587
  33. Guymer RH, Chong EW. Modifiable risk factors for age-related macular degeneration. Med J Aust. 2006;184:455–458
  34. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110:1273–1280
  35. Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL, et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology. 2003;110:25–33
  36. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697–704
  37. Tomany SC, Wang JJ, van Leeuwen R, Klein R, Mitchell P, Vingerling JR, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111:1280–1287
  38. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, van Duijn CM, Stricker BH, et al. Cholesterol and age-related macular degeneration: is there a link?. Am J Ophthalmol. 2004;137:750–752
  39. Chapman MJ. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther. 2007;113:184–196
  40. Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004;64:1181–1196
  41. Ferri C, Croce G, Cofini V, De Berardinis G, Grassi D, Casale R, et al. C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des. 2007;13:1631–1645
  42. Gemici G, Erdim R, Tokay S, Tezcan H, Fak AS, Oktay A. Interaction between C-reactive protein and endothelin-1 in coronary artery disease. Cardiology. 2007;107:340–344
  43. Ramzy D, Rao V, Tumiati LC, Xu N, Sheshgiri R, Jackman J, et al. Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein. J Thorac Cardiovasc Surg. 2007;133:1137–1146
  44. McGwin G, Hall TA, Xie A, Owsley C. The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol. 2005;89:1166–1170
  45. Klein R, Klein BE, Knudtson MD, Wong TY, Shankar A, Tsai MY. Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol. 2005;140:35–44
  46. Maeda S, Jesmin S, Iemitsu M, Otsuki T, Matsuo T, Ohkawara K, et al. Weight loss reduces plasma endothelin-1 concentration in obese men. Exp Biol Med (Maywood). 2006;231:1044–1047
  47. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114–1118
  48. Iglarz M, Schiffrin EL. Role of endothelin-1 in hypertension. Curr Hypertens Rep. 2003;5:144–148
  49. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun. 2000;269:713–717
  50. Agui T, Xin X, Cai Y, Sakai T, Matsumoto K. Stimulation of interleukin-6 production by endothelin in rat bone marrow-derived stromal cells. Blood. 1994;84:2531–2538
  51. Tsui JC, Dashwood MR. A role for endothelin-1 in peripheral vascular disease. Curr Vasc Pharmacol. 2005;3:325–332
  52. Topouzis F, Coleman AL, Harris A, Anastasopoulos E, Yu F, Koskosas A, et al. Prevalence of age-related macular degeneration in Greece: the Thessaloniki Eye Study. Am J Ophthalmol. 2006;142:1076–1079
  53. Bialek-Szymanska A, Misiuk-Hojlo M, Witkowska K. [Risk factors evaluation in age- related macular degeneration]. Klin Oczna. 2007;109:127–130

PII: S1875-6867(09)00364-9

doi: 10.1016/j.jomh.2009.10.003

journal of men's health
Volume 7, Issue 1 , Pages 85-91 , March 2010

Article Tools

* Image Usage & Resolution